Introduction (Word count=3130/4000)
Acute bacterial skin and skin structure infection (ABSSSI) and complicated skin and soft tissue infection (cSSTI) include cellulitis/erysipelas, wound infection, and major cutaneous abscess [1, 2] and impose a substantial burden on healthcare systems. Between 2005 and 2010, the incidence of skin and soft tissue infection in the United States was approximately 48 per 1000 person-years [3] ; currently, up to 300,000 surgical site infections occur each year, including those in skin and subcutaneous tissue [4] . Skin and soft tissue infections can be serious, requiring hospitalization and surgical procedures, and occasionally can cause bacteremia and death [5] . Factors associated with ABSSSI onset and clinical failures of ABSSSI treatment include obesity and low antibiotic dosage at discharge [6, 7] .
Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin antibiotic with in vitro activity against many of the common bacteria associated with ABSSSI, including S. aureus (both methicillin-susceptible [MSSA] and methicillinresistant [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, and non-ESBL producing Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca [8, 9] . In the
A C C E P T E D M
A N U S C R I P T 5 pivotal phase III CANVAS 1 and 2 trials, ceftaroline fosamil 600 mg given as a 1 hour IV infusion every 12 hours (q12h) was shown to be non-inferior to vancomycin plus aztreonam for the treatment of ABSSSI [10] [11] [12] . These results supported the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of ceftaroline fosamil 600 mg q12h (adjusted for renal function) for the treatment of adults with ABSSSI and cSSTI, respectively [8, 9] .
The presence of sepsis can impact the pharmacokinetics (PK) of some antibiotics and thus potentially affect antibiotic efficacy in patients with ABSSSI. Septic patients in the intensive care unit have shown increased volume of distribution and increased clearance.
An increase in volume of distribution in these patients has been shown to be due to capillary leak and endothelial damage, which can result in sub-therapeutic dosing following administration of antibiotics. Clearance is variable and is dependent on the individual's disease state. Variable exposure to drug as a result of changes in volumes and clearance can, in turn, result in variable responsiveness to treatment, in terms of both efficacy and toxicity, and this can impact mortality rates in these patients [13] [14] [15] .
The phase III COVERS trial was conducted to assess a ceftaroline fosamil dosage regimen of 600 mg as a 2 hour infusion every 8 hours (q8h) in patients with ABSSSI with systemic inflammatory response syndrome (SIRS) or underlying comorbidities and, on average, a greater lesion size [12] . Results from COVERS showed that ceftaroline fosamil 600 mg q8h was non-inferior to vancomycin plus aztreonam in these patients [12] . The objective of this post hoc analysis was to compare ceftaroline fosamil 600 mg q12h versus 600 mg q8h for the treatment of ABSSSI in patients with signs of sepsis, firstly by comparing clinical outcomes and pathogen susceptibilities in the COVERS trial
with the previously published CANVAS trials, and secondly by using population PK modeling to compare ceftaroline exposures in patients with or without markers of sepsis.
Material and Methods

Study Design
COVERS (NCT01499277) and CANVAS 1 and 2 (NCT00424190 and NCT00423657) were phase 3, multicenter, randomized, double-blind, comparative safety and efficacy trials of IV ceftaroline fosamil versus vancomycin plus aztreonam for the treatment of ABSSSI [10] [11] [12] . Patients were randomized to receive ceftaroline fosamil or vancomycin plus aztreonam at a ratio of 2:1 in COVERS and 1:1 in CANVAS 1 and 2. In COVERS, ceftaroline fosamil was administered at 600 mg q8h and vancomycin was administered at 15 mg/kg q12h with aztreonam at 1 g q8h. In CANVAS 1 and 2, ceftaroline fosamil was administered at 600 mg q12h and vancomycin plus aztreonam were each administered at 1 g q12h. Ceftaroline fosamil dosages were adjusted for patients with baseline creatinine clearance (CrCl) ≤50 mL/min and vancomycin plus aztreonam dosages were adjusted according to respective product labelling and institutional practice guidelines. Treatments were given for 5-14 days in all trials. The primary outcome measure for all three trials was clinical cure rate at test-of-cure (TOC) in the modified intent-to-treat (MITT) and clinically evaluable (CE) patient populations.
Patient and Disease Characteristics
The COVERS and CANVAS trials enrolled adult patients with cSSTI. The entire COVERS patient population, and a proportion of those in the CANVAS trials, met the FDA definition of ABSSSI [1] . Inclusion and exclusion criteria for the CANVAS trials ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 7 have been described previously [10, 11] ; in brief, patients had a diagnosis of cSSTI (defined as deep extensive cellulitis, major cutaneous abscess requiring surgical drainage, or infected wound, ulcer or burn) of sufficient severity to warrant hospitalization and ≥5 days of parenteral antibacterial therapy. Inclusion and exclusion criteria for COVERS were similar to the CANVAS trials, with an additional requirement of ABSSSI with surrounding area of erythema, edema, and/or induration with surface area ≥75 cm 2 , reflecting regulatory guidance at the time the study was initiated [1, 12] 
Microbiology
Baseline pathogen susceptibilities to ceftaroline (minimum inhibitory concentrations
[MICs]) were determined using Clinical and Laboratory Standards Institute methodology
[16] by a central reference laboratory.
Clinical Outcomes
Clinical cure was defined as the total resolution of all signs and symptoms of the baseline infection or improvement such that no further antimicrobial therapy was necessary.
Outcome was determined at the TOC time point (8-15 days after the last dose of study drug) in the MITT population (all randomized patients that received any study medication) and CE population, a subset of the MITT population that had a diagnosis of ABSSSI, had no non-eligible infections, received a prespecified minimum of study drug,
had an evaluation at the TOC (or were determined to be a clinical failure at end of therapy), and did not receive any systemically active antibacterial agents that may have affected the infection under study [12, 17] summarised by baseline pathogen. Safety was assessed in all randomized patients who received ≥1 dose of study therapy.
Population Pharmacokinetic Modeling
The ceftaroline population PK model used in this analysis was developed using a large patient PK dataset, which included data from 14 phase I trials in healthy subjects (with normal renal function or renal impairment), one phase II trial in patients with cSSTI, three phase III trials in patients with cSSTI (CANVAS 1, CANVAS 2, and COVERS) and three phase III trials in patients with community-acquired pneumonia [10] [11] [12] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
Patient PK data were obtained in COVERS, and in a subset of 45 patients in CANVAS 1
and 2 trials, by sparse PK sampling over a single dosing interval (ie 8 hours) on Day 3, with intensive PK samples taken in a subset of patients [29] . The population PK model was derived from first-order conditional estimation with the interaction model using the software program, NONMEM version 7.2.0 (ICON plc, Dublin, Ireland). Details related to the PK modeling have been previously described [30] . Ceftaroline PK profiles were estimated for individual patients in COVERS with available ceftaroline PK data. 
Statistical Analyses
Patient outcomes are presented using descriptive statistics and between-group outcome differences (95% CI) were determined using the Miettinen and Nurminen method [31] .
Full details of the statistical analyses used in the COVERS and CANVAS 1 and 2 trials have previously been described [10, 11] .
Results
Patient Demographics and Baseline Characteristics
Patient demographics and baseline characteristics are summarized in Table 1 . Most Compared with CANVAS 1 and 2, a greater proportion of patients in COVERS had elevated baseline C-reactive protein levels.
Baseline Pathogens
The most common pathogens isolated at baseline in the COVERS patient population Table 3 .
Clinical cure rates for ceftaroline fosamil−treated patients across all subgroups with systemic inflammatory signs or SIRS were broadly similar in the COVERS and CANVAS trials, ranging from 79% to 85% in COVERS and from 83% to 89% in the for the CE population were similar to those in the MITT (Supplemental Table 1 ). Table 1 ).
Clinical cure rates by baseline pathogen (ME population) are summarized in Table 4 . 
0%). The most common AEs among ceftaroline fosamil-treated patients
in CANVAS 1 and 2 (occurring in ≥3% of patients) were nausea (5.9%), headache (5.2%), diarrhea (4.9%), pruritus (3.5%), and rash (3.2%).
Population PK Modeling of Ceftaroline Exposures
Overall, the population PK modeling dataset included data from 951 subjects, of which 463 were patients with cSSTI. The model described the observed ceftaroline concentration data well, and was considered suitable to calculate exposure parameters for individual patients in COVERS. PK data were available from 371 patients in COVERS for whom a full ceftaroline plasma concentration time-course could be calculated.
Individual predictions of AUC ss and C max, ss for these patients are summarised by the presence or absence of fever, SIRS or bacteremia, high WBC count and CRP levels in 
Discussion
The compared to the CANVAS trials. This is likely due to patients generally having a more severe infection and comorbidities that are not captured in a single subgroup category.
Ceftaroline fosamil was well tolerated in both trials, with AEs representative of the cephalosporin class. Hence, the q12h regimen appears robust for the majority of patients with ABSSSI, regardless of the presence of systemic inflammatory signs.
These clinical data are aligned with population PK modeling of individual patients within the COVERS trial, which showed that steady state exposures of ceftaroline were comparable across patients with and without signs of sepsis. The PK of ceftaroline in COVERS were similar to results previously reported for subjects treated with ceftaroline fosamil q12h [18, 32] , with a dose-proportional increase in exposure from the q8h dosing used in COVERS [30, 32, 33] . Ceftaroline PK therefore does not appear to be affected by disease severity, suggesting that the ceftaroline fosamil q12h regimen provides adequate exposures in ABSSSI patients with severe disease. Pathogen susceptibilities to ceftaroline were similar between the COVERS and CANVAS trials, with both dosage regimens providing broad coverage against commonly isolated ABSSSI pathogens. The MICs of >95% of baseline isolates across the three trials were at or below respective CLSI and EUCAST susceptibility breakpoints for ceftaroline fosamil 600 mg q12h [16, 34] .
Clinical response rates were generally comparable across the COVERS and CANVAS trials for key ABSSSI pathogens, including S. aureus. MRSA isolated from COVERS and CANVAS 1 and 2 had ceftaroline MICs of ≤1 mg/L and ≤2 mg/L, respectively.
Probability of target attainment (PTA) analyses using the ceftaroline population PK model described above have shown that >95% PTA is predicted with the 600 mg q12h
dose regimen for S. aureus isolates with MICs up to 2 mg/L [30] . With the 600 mg q8h Because individual study patient PK data were not analyzed in this retrospective analysis and individual patients may have different states of disease, this was not described in the CANVAS and COVERS trials. We believe that confounds that do exist in this particular patient population are valid, but given the positive findings in our study, do not appear to play a substantial role in the efficacy or toxicity of ceftaroline treatment. In addition, because this analysis is a retrospective cross-trial comparison, it is limited by the inability to completely control for population differences between trials. Similarly, as enrollment for COVERS and the CANVAS trials occurred in different geographic locations, regional differences in care may have affected the results. However, given that the population PK analyses support the conclusions from the cross-trial comparison, the data overall support that ceftaroline fosamil 600 mg q12h is a robust dosage regimen for the great majority of patients with ABSSSI, including those with sepsis and SIRS.
Conclusions
On the basis of the clinical, microbiological and population PK modeling comparisons presented here, sepsis did not affect predicted individual steady state ceftaroline exposures. Ceftaroline fosamil 600 mg q12h is a well-tolerated, efficacious dosage
regimen for the majority of patients with severe ABSSSI, regardless of the extent of sepsis. c Severe local signs were erythema, swelling, tenderness, or warmth that was designated as "severe" by the investigator.
A C C E P T E D
d Systemic inflammatory response syndrome criteria were defined as presence of ≥2 of the following symptoms at baseline: temperature <36°C or >38°C; heart rate >90 beats per minute; respiratory rate >20 breaths per minute, or on blood gas, a PaCO 2 , <32 mmHg (4.3 kPa); WBCs <4000 cells/mm 3 or >12,000 cells/mm 3 , or >10% band forms (immature WBC). A C C E P T E D M A N U S C R I P T 30   Table 3 Clinical d Systemic inflammatory response syndrome criteria were defined as presence of ≥2 of the following symptoms at baseline: temperature <36°C or >38°C; heart rate >90 beats per minute; respiratory rate >20 breaths per minute, or on blood gas, a PaCO 2 , <32 mmHg (4.3 kPa); WBCs <4000 cells/mm 3 or >12,000 cells/mm 3 , or >10% band forms (immature WBC).
e Ceftaroline fosamil dosage regimens were adjusted for patients with CrCl >30-≤50 mL/min. Clinical cure rates for patients with CrCl >20-<30 mL/min (n=8) and patients with missing CrCl data (n=22) in COVERS not shown.
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